Fusen Pharmaceutical Co., Ltd. (HK:1652)
:1652
Want to see HK:1652 full AI Analyst Report?
Top Page
Fusen Pharmaceutical Co., Ltd.
(1652)
Select Model
Select Model
Rating:52Neutral
Price Target:
HK$1.00
▲(25.00% Upside)
Action:Reiterated
Date:05/11/26
The score is mainly driven by mixed financial performance: improving revenue and currently positive cash generation, but several years of losses and weaker margins keep risk elevated. Technical indicators are neutral-to-soft in the near term, while valuation (P/E ~11.9) provides only moderate support.
Positive Factors
Operating Cash Flow
Sustained positive operating cash flow in 2024–2025 provides a durable source of internal funding for working capital, modest capex, and short-term obligations. This strengthens liquidity and reduces immediate financing needs, supporting operational continuity while management executes a profit turnaround.
Negative Factors
Sustained Losses and Margin Pressure
Multi-year losses and compressed gross and operating margins erode returns, limit reinvestment capacity, and make profitability recovery a high priority. If margins remain weak, cash generation and shareholder returns will be constrained, forcing reliance on balance-sheet measures rather than organic strength.
Read all positive and negative factors
Positive Factors
Negative Factors
Operating Cash Flow
Sustained positive operating cash flow in 2024–2025 provides a durable source of internal funding for working capital, modest capex, and short-term obligations. This strengthens liquidity and reduces immediate financing needs, supporting operational continuity while management executes a profit turnaround.
Read all positive factors
Fusen Pharmaceutical Co., Ltd. (1652) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$764.63M
Dividend YieldN/A
Average Volume (3M)1.23M
Price to Earnings (P/E)11.9
Beta (1Y)0.13
Revenue Growth-15.98%
EPS Growth93.93%
CountryHK
Employees1,131
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)-0.02
Shares Outstanding739,301,000
10 Day Avg. Volume642,000
30 Day Avg. Volume1,233,253
Financial Highlights & Ratios
PEG Ratio0.48
Price to Book (P/B)1.48
Price to Sales (P/S)1.94
P/FCF Ratio7.59
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Fusen Pharmaceutical Co., Ltd. Business Overview & Revenue Model
Company Description
Fusen Pharmaceutical Company Limited, an investment holding company, manufactures and sells pharmaceutical products in the People's Republic of China. The company's product portfolio includes Shuanghuanglian-based cold medicines comprising Shuangh...
How the Company Makes Money
null...
Fusen Pharmaceutical Co., Ltd. Financial Statement Overview
Summary
Income Statement
32
Negative
Balance Sheet
54
Neutral
Cash Flow
62
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 273.37M | 326.03M | 565.61M | 491.76M | 385.66M |
| Gross Profit | 109.79M | 162.64M | 299.51M | 225.02M | 211.13M |
| EBITDA | 25.55M | -39.07M | 18.93M | 49.90M | 55.82M |
| Net Income | -11.78M | -188.78M | -36.28M | -34.65M | 16.64M |
Balance Sheet | |||||
| Total Assets | 1.26B | 1.24B | 1.34B | 1.35B | 1.24B |
| Cash, Cash Equivalents and Short-Term Investments | 83.88M | 21.06M | 34.85M | 128.11M | 81.70M |
| Total Debt | 324.34M | 383.69M | 344.12M | 228.38M | 240.69M |
| Total Liabilities | 891.02M | 869.80M | 781.52M | 737.38M | 582.39M |
| Stockholders Equity | 359.40M | 369.67M | 563.52M | 614.17M | 658.17M |
Cash Flow | |||||
| Free Cash Flow | 69.98M | 57.43M | -161.84M | 86.63M | -62.37M |
| Operating Cash Flow | 121.93M | 133.73M | -73.33M | 110.49M | 47.77M |
| Investing Cash Flow | -5.88M | -163.42M | -108.32M | -13.13M | -282.98M |
| Financing Cash Flow | -56.21M | 15.99M | 88.50M | -51.77M | 20.53M |
Fusen Pharmaceutical Co., Ltd. Technical Analysis
Neutral
0.80
Price Trends
1.19
Negative
1.01
Positive
0.82
Positive
Market Momentum
-0.03
Positive
45.33
Neutral
13.23
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1652, the sentiment is Neutral. The current price of 0.8 is below the 20-day moving average (MA) of 1.14, below the 50-day MA of 1.19, and below the 200-day MA of 0.82, indicating a neutral trend. The MACD of -0.03 indicates Positive momentum. The RSI at 45.33 is Neutral, neither overbought nor oversold. The STOCH value of 13.23 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for HK:1652.
Fusen Pharmaceutical Co., Ltd. Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
72 Outperform | HK$1.68B | 3.83 | 6.34% | 5.16% | 16.09% | -62.16% | |
60 Neutral | HK$659.50M | 9.05 | 5.66% | 2.92% | 2.57% | -1.27% | |
54 Neutral | HK$203.00M | -0.15 | -30.35% | ― | -11.89% | -290.48% | |
52 Neutral | HK$764.63M | 11.90 | -3.39% | ― | -15.98% | 93.93% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
46 Neutral | HK$367.75M | 43.63 | -1.17% | 7.50% | 59.60% | -351.02% | |
45 Neutral | HK$155.13M | -3.07 | -30.35% | ― | -12.03% | 6.24% |
* Healthcare Sector Average
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.10
0.81
279.31%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.07
0.02
40.00%
HK:0897
Wai Yuen Tong Medicine Holdings Limited
0.33
-0.02
-5.71%
HK:0950
Lee's Pharmaceutical Holdings Limited
1.14
-0.23
-16.79%
HK:1498
PuraPharm Corp. Ltd.
0.30
-0.24
-44.44%
HK:2348
Dawnrays Pharmaceutical Holdings Ltd.
1.12
0.03
2.75%
Fusen Pharmaceutical Co., Ltd. Corporate Events
Fusen Pharmaceutical Wins China Approval for New Lornoxicam Injection
May 11, 2026
Fusen Pharmaceutical has secured Chinese regulatory approval to market its Lornoxicam for Injection, developed by its wholly owned subsidiary Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology, for the short-term treatment of moderate acute post-o...
Fusen Pharmaceutical Sets 2026 AGM to Renew Board, Auditor and Share Issuance Mandate
Apr 30, 2026
Fusen Pharmaceutical Company Limited has called its annual general meeting for 29 May 2026 in Hong Kong, where shareholders will review and adopt the audited consolidated financial statements and directors’ and auditors’ reports for th...
Fusen Pharma Wins Mainland China Approval for New Dydrogesterone Tablet
Apr 27, 2026
Fusen Pharmaceutical said its wholly owned unit Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology has secured National Medical Products Administration approval in China to market Dydrogesterone Tablet, branded Yunmeiyan, for a range of conditions...
Fusen Pharmaceutical Wins China Approval for Glucosamine Osteoarthritis Capsule
Apr 17, 2026
Fusen Pharmaceutical has secured Chinese regulatory approval for its Glucosamine Sulfate Capsule, marketed under the Shuhuitong brand, for treating primary and secondary osteoarthritis. The product, based on natural amino monosaccharides that supp...
Fusen Pharmaceutical Switches Auditor After Dispute Over 2025 Audit Fee
Apr 10, 2026
Fusen Pharmaceutical has issued a supplemental announcement detailing the circumstances behind its recent change of auditor, following the resignation of KPMG over a dispute on the audit fee for the 2025 financial year. After KPMG proposed a subst...
Fusen Pharmaceutical Narrows Annual Loss Despite Revenue Decline
Mar 31, 2026
Fusen Pharmaceutical reported revenue of RMB273.4 million for 2025, down 16.2% year on year, with gross profit falling 32.5% and gross margin narrowing from 49.9% to 40.2%. The board decided not to distribute a final dividend for 2025, in line wit...
Fusen Pharmaceutical Sets March 2026 Board Meeting to Approve 2025 Results
Mar 19, 2026
Fusen Pharmaceutical Company Limited has scheduled a board meeting for 31 March 2026 to review and approve the annual results of the company and its subsidiaries for the financial year ended 31 December 2025. The board will also consider the possi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.